Compare WEAV & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WEAV | FHTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.7M | 360.5M |
| IPO Year | 2021 | 2020 |
| Metric | WEAV | FHTX |
|---|---|---|
| Price | $7.28 | $6.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $11.00 | ★ $11.50 |
| AVG Volume (30 Days) | ★ 1.2M | 198.6K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 7.50 | ★ 25.32 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $239,024,000.00 | $30,909,000.00 |
| Revenue This Year | $17.20 | $8.89 |
| Revenue Next Year | $13.74 | $20.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 16.99 | ★ 36.75 |
| 52 Week Low | $4.24 | $3.27 |
| 52 Week High | $8.11 | $6.95 |
| Indicator | WEAV | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.11 | 69.79 |
| Support Level | $6.71 | $4.43 |
| Resistance Level | $7.35 | N/A |
| Average True Range (ATR) | 0.32 | 0.45 |
| MACD | 0.01 | 0.14 |
| Stochastic Oscillator | 99.06 | 95.19 |
Weave Communications Inc is a customer experience and payments software platform tailored for SMB healthcare businesses that revolutionizes patient interaction from initial contact to billing. It integrates diverse workflows into a unified solution, minimizing manual tasks and maximizing patient engagement. Weave democratizes enterprise-level communication tools, simplifying them for SMBs in a singular platform. Offering varied communication channels, appointment scheduling, payment processing, and more enhances practitioner-patient relationships and optimizes practice operations. The company has a singular operating segment and generates revenue mainly from subscriptions.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.